The Epigenetics of Lung Cancer Dormancy and Relapse

Patients who complete lung cancer treatment and enter remission may still harbor disease that remains biologically active but clinically silent. A review by Federico Pio Fabrizio examines that concealed interval, focusing on how dormant tumor cells persist and later drive relapse despite initial therapeutic success.

Here’s a brief summary of the review.

Dormancy as a Clinically Relevant State

Tumor dormancy in lung cancer reflects a reversible arrest in proliferation that enables disseminated tumor cells to survive initial therapy and remain undetected. These cells typically reside in the G0/G1 phase while maintaining viability and the capacity to re-enter the cell cycle. The review describes dormancy as a key contributor to minimal residual disease and late recurrence, particularly in both non-small cell and small cell lung cancer.

Dormant cells evade therapy largely because most treatments target actively dividing populations. At the same time, immune-mediated pressures and limited angiogenesis can constrain tumor expansion, creating a state in which proliferation and cell death are balanced or paused. Autophagy supports survival under metabolic stress, while immune escape mechanisms, including checkpoint signaling, allow these cells to persist in an immunocompetent host.

Epigenetic Regulation as a Central Driver

The review identifies epigenetic mechanisms as central to maintaining dormancy. DNA methylation, histone modifications, and non-coding RNAs act together to suppress proliferative gene expression while preserving cellular viability. DNA methyltransferases, including DNMT1, DNMT3A, and DNMT3B, establish and maintain methylation patterns that silence genes involved in cell cycle progression, apoptosis, and DNA repair.

Histone-based regulation further stabilizes this transcriptionally repressive state. The polycomb repressive complex, through EZH2-mediated trimethylation of histone H3 lysine 27, suppresses genes associated with proliferation and differentiation. Histone deacetylases and demethylases dynamically regulate chromatin accessibility, allowing cells to remain quiescent while retaining the ability to reactivate.

Non-coding RNAs add another layer of control. MicroRNAs such as the miR-29 family influence DNA methyltransferase activity and broader epigenetic landscapes, while others regulate pathways linked to metabolism, epithelial–mesenchymal transition, and resistance. These interactions create a coordinated system that reinforces dormancy yet preserves plasticity.

Metabolic and Microenvironmental Integration

Dormant cells display metabolic adaptations that reinforce their epigenetic state. Reduced glycolysis and increased reliance on oxidative phosphorylation alter the availability of metabolites such as acetyl-CoA and NAD+, which directly influence chromatin-modifying enzymes. These changes support a transcriptionally repressive environment while maintaining readiness for reactivation.

The tumor microenvironment plays a critical role in sustaining dormancy. The diagram on page 3 illustrates how disseminated tumor cells settle within the lung and enter a dormant state regulated by epigenetic and adaptive survival mechanisms. Interactions with the extracellular matrix through integrins activate signaling pathways including FAK, MAPK, and PI3K/AKT, promoting survival and cell cycle arrest.

Cytokines such as TGF-β and IL-6, along with hypoxia-driven signaling, further modulate epigenetic regulators and reinforce quiescence. Immune dynamics also contribute, as cytotoxic T cells can maintain dormancy through cytokine signaling, while regulatory immune populations create an environment that supports persistence.

Therapeutic Implications and Clinical Detection

The persistence of dormant cells underlies the limitations of current lung cancer treatments. Conventional therapies reduce tumor burden but often fail to eliminate quiescent populations, allowing relapse to occur months or years later. The review outlines therapeutic approaches that aim to maintain dormancy, induce reactivation to sensitize cells to treatment, or directly eliminate dormant cells.

Epigenetic therapies are central to these strategies. Inhibitors targeting DNA methylation, histone modification, and chromatin remodeling enzymes are under investigation in both preclinical and clinical settings. These agents aim to disrupt the regulatory networks that sustain dormancy or to alter tumor cell states in ways that improve treatment response.

Detection remains a challenge because dormant cells are not readily identified by standard imaging. Liquid biopsy approaches, including circulating tumor cells and extracellular vesicles, are being explored as methods to monitor minimal residual disease and detect early reactivation.

Chemotherapy may also contribute to dormancy by selectively eliminating proliferating cells while sparing quiescent ones. This process reinforces epigenetic programs associated with cell cycle arrest and stress adaptation, creating a population of therapy-resistant cells that can later drive recurrence.

Implications for Long-Term Disease Control

Dormant lung cancer cells maintain a reversible and adaptive epigenetic landscape that supports survival under therapeutic and environmental pressure. This plasticity enables transitions between quiescence and proliferation, sustaining the risk of relapse even after apparent disease control.

Efforts to improve long-term outcomes will depend on identifying dormancy-specific biomarkers and developing strategies that target these epigenetic states. A clearer understanding of how dormant cells persist and reactivate informs both monitoring approaches and therapeutic design, shaping the direction of future lung cancer management.

Reference:
Fabrizio FP. Unlocking Lung Cancer Cell Dormancy: An Epigenetic Perspective. International Journal of Molecular Sciences. 2025; 26(22):10997. https://doi.org/10.3390/ijms262210997